BioPharma Resources

Drug Trial Radar · NCT02832063

Clinical Trial in Subjects With Mild to Moderate Acne Vulgaris

A Randomized, Double Blinded, Phase IIb/III, Decentralized Study of B244 Delivered as a Topical Spray to Determine Safety and Efficacy in Participants With Mild to Moderate Acne Vulgaris

Last checked: Nov 19, 2026Latest source record: Sep 16, 2022 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 372 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

372

Actual

Start

Aug 2016

Primary completion

Jul 19, 2017

Study completion Jul 19, 2017

Sponsor

Lead sponsor
AOBiome LLCIndustry
Sponsor type
Industry
First posted
Jul 13, 2016

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2 / Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to demonstrate the safety, tolerability and efficacy of B244 administered over 12 weeks to participants with mild to moderate acne vulgaris relative to placebo.

Conditions

  • Acne Vulgaris

Interventions

  • B244Biological

    4 pumps of spray to saturate the entire face applied BID. Applications should occur in the morning and at night for 12 weeks.

  • PlaceboBiological

    4 pumps of spray to saturate the entire face applied BID. Applications should occur in the morning and at night for 12 weeks.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Participants With Treatment RelatedAdverse EventsTime frame: 16 weeks
  2. Change in Inflammatory and Non-inflammatory Lesion CountTime frame: 12 weeks
  3. Number of Participants Demonstrating Efficacy Measured by Investigator Global Assessment SuccessTime frame: 12 weeks

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Science37

    Culver City, California

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.